

Supplementary Table 19. Time persistence effect on cholecystitis and cholangitis development following zoster vaccination

Time (yr)	Events, n (%)	aHR (95% CI)	
		Model 1 ^{a)}	Model 2 ^{b)}
< 1			
Unvaccinated	1,949 (0.27)	1.0 (reference)	1.0 (reference)
Vaccinated	1,631 (0.22)	0.84(0.78 to 0.89)c)	0.83 (0.78 to 0.89) ^{c)}
1–2			
Unvaccinated	1,917 (0.26)	1.0 (reference)	1.0 (reference)
Vaccinated	1,605 (0.22)	0.84(0.78 to 0.89) ^{c)}	0.83 (0.78 to 0.89) ^{c)}
2–4			
Unvaccinated	3,052 (0.42)	1.0 (reference)	1.0 (reference)
Vaccinated	2,353 (0.32)	0.81 (0.76to 0.85) ^{c)}	0.81 (0.77 to 0.85) ^{c)}
4–6			
Unvaccinated	1,720 (0.24)	1.0 (reference)	1.0 (reference)
Vaccinated	1,246 (0.17)	0.85 (0.79 to 0.91) ^{c)}	0.83 (0.77 to 0.89) ^{c)}
6–8			
Unvaccinated	517 (0.07)	1.0 (reference)	1.0 (reference)
Vaccinated	345 (0.05)	0.85 (0.74 to 0.97) ^{c)}	0.81 (0.71 to 0.93) ^{c)}
≥8			
Unvaccinated	21 (0.003)	1.0 (reference)	1.0 (reference)
Vaccinated	17 (0.002)	1.09 (0.57 to 2.07)	1.17 (0.61 to 2.24)

aHR, adjusted hazard ratio; CI, confidence interval.

^{a)}Models 1: adjusted for age (50–54, 55–59, 60-64, and \geq 65 years) and sex.

^{b)}Model 2: adjusted for age (50–54, 55–59, 60-64, and \geq 65 years); sex; household income (low income, middle income, and high income); region of residence (urban and rural); Charlson comorbidity index (0, 1, and \geq 2); obesity (underweight [< 18.5 kg/m²], normal [18.5–22.9 kg/m²], overweight [23.0–24.9 kg/m²], and obese [\geq 25.0 kg/m²]); blood pressure (systolic blood pressure < 140 mmHg and diastolic blood pressure < 90 mmHg and systolic blood pressure \geq 140 mmHg or diastolic blood pressure \geq 90 mmHg); fasting blood glucose (< 100 and \geq 100 mg/dL); glomerular filtration rate (< 60, 60–89, and \geq 90 mL/min/1.73 m²); smoking status (non-, ex-, and current smoker); alcohol consumption (drinks; < 1, 1–2, 3–4, and \geq 5 days per week); aerobic physical activity (sufficient and insufficient); and history of medication use for coronary artery disease, diabetes mellitus, dyslipidemia, and hypertension.

^{c)}Significant differences (p < 0.05).